{
    "clinical_study": {
        "@rank": "67095", 
        "arm_group": {
            "arm_group_label": "Long term follow up", 
            "arm_group_type": "Other", 
            "description": "Long term follow up of patient's who received ProSavin in previous study"
        }, 
        "brief_summary": {
            "textblock": "The study is designed to assess the long term tolerability of ProSavin and whether it is\n      safe and efficacious in patients administered ProSavin from the PS1/001/07 study ."
        }, 
        "brief_title": "Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease", 
        "completion_date": {
            "#text": "May 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  must have met all inclusion criteria for study PS1/001/07\n\n          -  willing to have L-DOPA dosage reduced/withdrawn at the discretion of the\n             investigator at regular intervals to allow assessment of ProSavin in the absence of\n             concomitant antiparkinsonian medication.\n\n          -  affiliated with the French social security health care system (Patients enrolled in\n             France only)\n\n          -  signed and dated written informed consent obtained from the patient and/or the\n             patient's legally acceptable representative, if applicable, in accordance with the\n             local regulations\n\n          -  must have been treated with ProSavin/Sham\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856439", 
            "org_study_id": "PS1/001/09", 
            "secondary_id": "2009-017253-35"
        }, 
        "intervention": {
            "arm_group_label": "Long term follow up", 
            "description": "Long term follow up of patients who received ProSavin in a previous study", 
            "intervention_name": "ProSavin", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ProSavin", 
            "Gene therapy"
        ], 
        "lastchanged_date": "May 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Henri Mondor Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Addenbrookes Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.", 
        "overall_official": [
            {
                "affiliation": "Henri Mondor Hospital", 
                "last_name": "Stephane Palfi, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Addenbrookes Hospital", 
                "last_name": "Roger Barker, Dr", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number and severity of any adverse event", 
            "measure": "To assess the long term safety and tolerability of ProSavin", 
            "safety_issue": "Yes", 
            "time_frame": "10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856439"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessed using Unified Parkinson's Disease Rating Score(UPDRS) Part III, evaluating percentage of time during waking day that patient is in the \"off\" state through patient diaries and activities of daily living using PDQ-39 at 36 months post administration.", 
            "measure": "Patients' responses to ProSavin administration", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "source": "Oxford BioMedica", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oxford BioMedica", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}